Search
Now showing items 91-100 of 132
Desmoplastic small round cell tumor (DSRCT): emerging therapeutic targets and future directions for potential therapies.
(TAYLOR & FRANCIS LTD, 2020-04-02)
Novel therapeutic strategies targeting telomere maintenance mechanisms in high-risk neuroblastoma.
(BMC, 2020-05-06)
The majority of high-risk neuroblastomas can be divided into three distinct molecular subgroups defined by the presence of MYCN amplification, upstream TERT rearrangements or alternative lengthening of telomeres (ALT). The ...
Development of a cell-free split-luciferase biochemical assay as a tool for screening for inhibitors of challenging protein-protein interaction targets.
(F1000 Research Ltd, 2020-01-01)
Targeting the interaction of proteins with weak binding affinities or low solubility represents a particular challenge for drug screening. The NanoLuc â ® Binary Technology (NanoBiT â ®) was originally developed to detect ...
A potent KRAS macromolecule degrader specifically targeting tumours with mutant KRAS.
(NATURE PUBLISHING GROUP, 2020-06-26)
Tumour-associated KRAS mutations are the most prevalent in the three RAS-family isoforms and involve many different amino-acids. Therefore, molecules able to interfere with mutant KRAS protein are potentially important for ...
Salmonella-based platform for efficient delivery of functional binding proteins to the cytosol.
(NATURE PUBLISHING GROUP, 2020-07-03)
Protein-based affinity reagents (like antibodies or alternative binding scaffolds) offer wide-ranging applications for basic research and therapeutic approaches. However, whereas small chemical molecules efficiently reach ...
Competitive SPR using an intracellular anti-LMO2 antibody identifies novel LMO2-interacting compounds.
(ELSEVIER, 2021-03-29)
The use of intracellular antibodies as templates to derive surrogate compounds is an important objective because intracellular antibodies can be employed initially for target validation in pre-clinical assays and subsequently ...
SLFN11 informs on standard of care and novel treatments in a wide range of cancer models.
(SPRINGERNATURE, 2021-03-02)
BACKGROUND: Schlafen 11 (SLFN11) has been linked with response to DNA-damaging agents (DDA) and PARP inhibitors. An in-depth understanding of several aspects of its role as a biomarker in cancer is missing, as is a ...
Targeting therapeutic vulnerabilities associated with EWS fusion proteins in Ewing sarcoma
(Institute of Cancer Research (University Of London), 2021-01-31)
Ewing sarcoma (ES) is a are and aggressive bone tumour affecting children and young adults and that requires better therapeutic options to improve patient outcomes. ES is characterised by chromosomal rearrangements producing ...
Circulating tumour DNA sequencing to determine therapeutic response and identify tumour heterogeneity in patients with paediatric solid tumours.
(ELSEVIER SCI LTD, 2021-12-18)
OBJECTIVE: Clinical diagnostic sequencing of circulating tumour DNA (ctDNA) is well advanced for adult patients, but application to paediatric cancer patients lags behind. METHODS: To address this, we have developed a ...